サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：核医学の世界市場の評価：タイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
市場調査レポート
商品コード
1402438

核医学の世界市場の評価：タイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）

Nuclear Medicine Market Assessment, By Type, By Application, By End-users, By Region, Opportunities and Forecast, 2017-2031F
出版日: | 発行: Market Xcel - Markets and Data | ページ情報: 英文 220 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
核医学の世界市場の評価：タイプ別、用途別、エンドユーザー別、地域別、機会、予測（2017年～2031年）
出版日: 2024年01月08日
発行: Market Xcel - Markets and Data
ページ情報: 英文 220 Pages
納期: 3～5営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の核医学の市場規模は、2023年に101億米ドル、2031年に253億8,000万米ドルに達し、2024年～2031年の予測期間にCAGRで12.21％の成長が見込まれています。市場は、強力な市場企業と強力な技術のプレゼンスにより、非常にダイナミックで有望です。市場は、市場成長に寄与する慢性疾患の流行や技術の進歩などの要因により成長しています。

WHOによると、心血管疾患、脳卒中、がん、糖尿病は世界の主要な死因です。これらの疾患による死亡率の増加が、世界の核医学を牽引すると予測されます。がんや神経疾患などの標的疾患に対する新たな治療オプションを開発するための放射性医薬品分野における技術の進歩が、核医学市場の成長を促進しています。有利な政府政策が世界の核医学市場の成長に寄与しています。しかし、高額な資本投資、規制遵守、サプライチェーンの混乱、熟練した専門家の不足などの障害が市場の成長に影響を与える可能性があります。

標的疾患の流行

標的疾患の流行は核医学市場の重要な促進要因です。がん、心血管疾患などの慢性疾患の発生率と有病率の増加が核医学処置への需要を促進しています。核医学はこれらの疾患の診断と治療において重要な役割を果たしており、先進の診断と治療の選択肢に対する需要の向上につながっています。特定の疾患マーカーを同定し、治療に対する個々の反応を予測する核医学技術の能力は、その採用を促進し、市場拡大にさらに寄与しています。2021年の死亡者数は、心血管疾患が2,050万人、がんが1,000万人、糖尿病が670万人となっています。

技術の進歩

急速な技術の進歩が世界の核医学市場を牽引しています。画像診断や治療技術の向上、治療計画に向けた迅速で正確な診断といった重要な進歩が核医学市場を牽引しています。さらに、放射性トレーサーと放射性同位元素の生産における進歩は、より的を絞った効果的な核医学治療の開発を可能にしています。核医学におけるAIと機械学習（ML）の統合は、この分野の大幅な進歩を促進しています。

ML、ディープラーニング、人工ニューラルネットワーク、畳み込みニューラルネットワークを含むAIは、核医学イメージングにおける精密医療の開発において重要な役割を果たしています。これらの技術は、医用画像のワークフローを自動化し、計画、画像取得、解釈など、核医学における典型的な医用画像のワークフローのすべての段階に適用されています。

政府の取り組みと研究開発における資金提供の増加

核医学の開発と製造への投資の増加は、成長と拡大を促進することで市場にプラスの影響を与えています。複数の投資家が核医学の研究開発と技術革新に巨額の資金を提供しています。資金提供と投資の増加は、核医学技術を進歩させ、診断と治療への応用を拡大する上で極めて重要な役割を果たしており、市場の大幅な成長をもたらしています。

北米が世界の核医学市場を独占

北米は2022年のマーケットリーダーであり、今後も急速な発展が見込まれます。強力な医療インフラ、多数の核医学手術、研究開発への莫大な投資が、この地域の大きな市場シェアに寄与しています。

COVID-19の影響

COVID-19パンデミックは核医学市場に大きな影響を与えました。COVID-19患者の優先治療と院内感染による病院活動の閉鎖は、核医学の手技と収益の減少につながっています。核医学研究の分野と放射性医薬品産業はパンデミックの悪影響を受け、がん検診の件数が大幅に減少しました。パンデミックは放射性医薬品のサプライチェーンを阻害しました。2021年、患者数の増加と病院やその他の医療施設における医療処置の復旧により、市場企業の収益は徐々に増加しました。パンデミックは核医学市場に大きな課題をもたらし、業界はニューノーマルに適応し、影響を緩和する戦略を実施する必要があります。

当レポートでは、世界の核医学市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢と見通しなどを提供しています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 世界の核医学市場に対するCOVID-19の影響

第4章 エグゼクティブサマリー

第5章 世界の核医学市場の見通し（2017年～2031年）

  • 市場規模と予測
    • 金額
    • 数量
  • タイプ別
    • 診断核医学
    • 治療核医学
  • 用途別
  • エンドユーザー別
  • 地域別
  • 市場シェア：企業別（2023年）
  • 北米
    • 市場規模と予測
    • タイプ別
    • 用途別
    • エンドユーザー別
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • フランス
    • イタリア
    • 英国
    • ロシア
    • オランダ
    • スペイン
    • トルコ
    • ポーランド
  • 南米
    • ブラジル
    • アルゼンチン
  • アジア太平洋
    • インド
    • 中国
    • 日本
    • オーストラリア
    • ベトナム
    • 韓国
    • インドネシア
    • フィリピン
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • 南アフリカ

第6章 市場マッピング（2023年）

  • タイプ別
  • 用途別
  • エンドユーザー別
  • 地域別

第7章 マクロ環境と産業構造

  • 需給分析
  • 輸出入の分析 - 数量と金額
  • サプライ/バリューチェーン分析
  • PESTEL分析
  • ポーターのファイブフォース分析

第8章 市場力学

  • 成長促進要因
  • 成長抑制要因（課題、抑制要因）

第9章 規制の枠組みとイノベーション

  • 臨床試験
  • 特許情勢
  • 規制当局の承認
  • イノベーション/新技術

第10章 主要企業情勢

  • マーケットリーダー上位5社の競合マトリクス
  • マーケットリーダー上位5社の市場収益分析（2023年）
  • 合併と買収/合弁事業（該当する場合）
  • SWOT分析（市場参入企業5社）
  • 特許分析（該当する場合）

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

  • GE Healthcare
  • Cardinal Health
  • Jubilant Life Sciences Ltd
  • Curium Pharma
  • Nordion Inc.
  • Bracco Imaging S.P.A
  • NTP Radioisotopes SOC Ltd.
  • EczacIbasI-Monrol Nuclear Products
  • Lantheus Medical Imaging Inc
  • Eckert & Ziegler
  • Mallinckrodt

第14章 戦略的推奨事項

第15章 当社について、免責事項

図表

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 2. Global Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 3. Global Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 5. Global Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 6. Global Nuclear Medicine Market Share (%), By Region, 2017-2031F
  • Figure 7. North America Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 8. North America Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 9. North America Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 10. North America Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 11. North America Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 12. North America Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 13. United States Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 14. United States Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 15. United States Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 16. United States Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 17. United States Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 18. Canada Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 19. Canada Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 20. Canada Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 21. Canada Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 22. Canada Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 23. Mexico Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 24. Mexico Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 25. Mexico Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 26. Mexico Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 27. Mexico Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 28. Europe Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 29. Europe Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 30. Europe Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 31. Europe Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 32. Europe Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 33. Europe Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 34. Germany Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 35. Germany Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 36. Germany Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 37. Germany Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 38. Germany Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 39. France Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 40. France Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 41. France Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 42. France Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 43. France Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 44. Italy Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 45. Italy Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 46. Italy Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 47. Italy Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 48. Italy Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 49. United Kingdom Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 50. United Kingdom Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 51. United Kingdom Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 52. United Kingdom Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 53. United Kingdom Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 54. Russia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 55. Russia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 56. Russia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 57. Russia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 58. Russia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 59. Netherlands Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 60. Netherlands Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 61. Netherlands Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 62. Netherlands Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 63. Netherlands Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 64. Spain Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 65. Spain Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 66. Spain Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 67. Spain Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 68. Spain Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 69. Turkey Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 70. Turkey Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 71. Turkey Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 72. Turkey Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 73. Turkey Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 74. Poland Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 75. Poland Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 76. Poland Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 77. Poland Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 78. Poland Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 79. South America Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 80. South America Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 81. South America Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 82. South America Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 83. South America Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 84. South America Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 85. Brazil Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 86. Brazil Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 87. Brazil Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 88. Brazil Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 89. Brazil Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 90. Argentina Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 91. Argentina Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 92. Argentina Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 93. Argentina Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 94. Argentina Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 95. Asia-Pacific Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 96. Asia-Pacific Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 97. Asia-Pacific Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 98. Asia-Pacific Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 99. Asia-Pacific Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 100. Asia-Pacific Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 101. India Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 102. India Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 103. India Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 104. India Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 105. India Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 106. China Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 107. China Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 108. China Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 109. China Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 110. China Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 111. Japan Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 112. Japan Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 113. Japan Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 114. Japan Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 115. Japan Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 116. Australia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 117. Australia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 118. Australia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 119. Australia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 120. Australia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 121. Vietnam Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 122. Vietnam Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 123. Vietnam Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 124. Vietnam Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 125. Vietnam Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 126. South Korea Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 127. South Korea Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 128. South Korea Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 129. South Korea Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 130. South Korea Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 131. Indonesia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 132. Indonesia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 133. Indonesia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 134. Indonesia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 135. Indonesia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 136. Philippines Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 137. Philippines Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 138. Philippines Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 139. Philippines Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 140. Philippines Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 141. Middle East & Africa Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 142. Middle East & Africa Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 143. Middle East & Africa Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 144. Middle East & Africa Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 145. Middle East & Africa Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 146. Middle East & Africa Nuclear Medicine Market Share (%), By Country, 2017-2031F
  • Figure 147. Saudi Arabia Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 148. Saudi Arabia Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 149. Saudi Arabia Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 150. Saudi Arabia Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 151. Saudi Arabia Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 152. UAE Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 153. UAE Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 154. UAE Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 155. UAE Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 156. UAE Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 157. South Africa Nuclear Medicine Market, By Value, in USD Billion, 2017-2031F
  • Figure 158. South Africa Nuclear Medicine Market, By Volume, in Million Units, 2017-2031F
  • Figure 159. South Africa Nuclear Medicine Market Share (%), By Type, 2017-2031F
  • Figure 160. South Africa Nuclear Medicine Market Share (%), By Applications, 2017-2031F
  • Figure 161. South Africa Nuclear Medicine Market Share (%), By End-users, 2017-2031F
  • Figure 162. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 163. By Applications Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 164. By End-users Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023
目次
Product Code: MX10819

Global nuclear medicine market size was valued at USD 10.1 billion in 2023, which is expected to reach USD 25.38 billion in 2031, with a CAGR of 12.21% for the forecast period between 2024 and 2031F. The global nuclear medicine market is highly dynamic and promising, with the presence of strong market players and robust technologies. The global nuclear medicine market is experiencing growth due to factors such as increasing prevalence of chronic diseases and technological advancements that are contributing towards growth of the market.

According to WHO, cardiovascular diseases, stroke, cancer, and diabetes are among the leading causes of death globally. Increasing mortality rates due to these diseases are expected to drive the global nuclear medicine. Technological advancements in the field of radiopharmaceuticals for the development of new treatment options for targeted conditions such as cancer and neurological disorders are promoting growth in the nuclear medicine market. Favorable government policies are contributing towards the growth of the global nuclear medicine market. However, hindrances such as high capital investment, regulatory compliance, supply chain disruptions and lack of skilled professionals can impact the growth of the market.

In August 2023, NorthStar Medical Radioisotopes, LLC, and Curadh MTR Inc. (Curadh) announced a strategic long-term supply agreement for the therapeutic radioisotope non-carrier added actinium-225 (Ac-225). Under this agreement, NorthStar will provide radioisotope non-carrier added actinium-225 (Ac-225) to Curadh for the development of treatment of lethal tumors.

Growing Prevalence of Targeted Conditions

The growing prevalence of targeted conditions is a significant driver of the nuclear medicine market. The increasing incidence and prevalence of cancer, cardiovascular diseases, and other chronic ailments are fueling the demand for nuclear medicine procedures. Nuclear medicine plays a substantial role in the diagnosis and treatment of these diseases, leading to a rising demand for advanced diagnostic and therapeutic options. The ability of nuclear medicine techniques to identify specific disease markers and predict individual responses for treatment is driving their adoption, further contributing to market expansion. Cardiovascular deaths accounted for 20.5 million deaths, cancer accounted for 10 million deaths and diabetes accounting for 6.7 million deaths in 2021.

Technological Advancements

Rapid technological advancements are driving the market for global nuclear medicine. Key advancements, such as improved imaging and therapeutic techniques and faster and accurate diagnosis for treatment planning are driving the market for nuclear medicine. Additionally, advancements in radiotracers and radioisotope production have enabled the development of more targeted and effective nuclear medicine treatments. The integration of artificial intelligence (AI) and machine learning (ML) in nuclear medicine is driving significant advancements in the field.

AI, including ML, deep learning, artificial neural networks, and convolutional neural networks, is playing a crucial role in developing precision medicine in nuclear medicine imaging. These technologies are automating the workflow of medical imaging and are being applied to all phases of a typical medical imaging workflow in nuclear medicine, including planning, image acquisition, and interpretation. In June 2023, Siemens Healthineers announced the launch of FDA-approved POSLUMA (flotufolastat F 18) injection to be used as PET imaging agent. The injection is manufactured and distributed by PETNET Solution. Siemens Healthineers launched its product at SNMMI 2023 annual meeting (Society of Nuclear Medicine and Molecular Imaging).

Increasing Funding in Government Initiatives and Research and Development

Increasing investment in nuclear medicine development and manufacturing is positively impacting the market by driving growth and expansion. Several investors are providing huge amount of funds for doing research and development and innovation in nuclear medicines. Government initiatives and funding for the development of new techniques, such as USD 70,000 funding received by Charles Sturt University to develop and offer a new micro credential course in nuclear medicine. Increasing funding and investments are playing a pivotal role in advancing nuclear medicine technologies and expanding their applications in diagnosis and treatment, leading to substantial market growth. In July 2022, Framatome announced buying minor stakes in Global Morpho Pharma. With this investment, Framatome aims to expand its assistance for the supply chain of Lutetium-177 and other prospective isotopes for therapeutic uses and improve its operations supporting the development of nuclear medicine.

North America Dominates the Global Nuclear Medicine Market

North America was the market leader in 2022 and is expected to continue to develop rapidly in the coming years. Strong healthcare infrastructure, a high volume of nuclear medicine procedures, and huge investment in research and development contribute to the region's significant market share.

In 2021, GE Healthcare & NorthStar Medical Radioisotopes signed a manufacturing and distribution agreement in the United States. The pharmaceutical diagnostics division of GE Healthcare will use a brand-new, cutting-edge production system at its Arlington Heights facility to manufacture and supply NorthStar with I-123 capsules under the NorthStar label.

Impact of COVID-19

The COVID-19 pandemic had a significant impact on the nuclear medicine market. The prioritization of COVID-19 patients and closure of hospital activities due to hospital-acquired infections led to a reduction in procedure volume and revenue in nuclear medicine. The field of nuclear medicine research and the radiopharmaceutical industry were adversely affected by the pandemic, with a significant reduction in procedure volumes for cancer screening. The pandemic hindered the supply chain of radiopharmaceuticals. Revenue for market players increased gradually in 2021, due to rise in patient volumes and the restoration of medical procedures in hospitals and other healthcare facilities. The pandemic posed significant challenges to the nuclear medicine market, requiring the industry to adapt to the new normal and implement strategies to mitigate the impact.

Key Players Landscape and Outlook

Market players are expanding their product offerings and giving patients access to a wider range of innovative technologies. Companies are expanding the range of products and services they offer to gain market share. Industry participants use a variety of growth strategies such as collaborations, mergers and acquisitions, and go-to-market strategies.

In October 2023, Cyclopharm announced that USFDA approval of its nuclear medicine called Technegas which is used for the diagnosis and management of pulmonary embolism. Technegas has already been used in more than 64 countries serving 4.7 million patients.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Nuclear Medicine Market

4. Executive Summary

5. Global Nuclear Medicine Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Type
    • 5.2.1 Diagnostic Nuclear Medicine
      • 5.2.1.1. PET Radiopharmaceuticals
      • 5.2.1.1.1. FDG-PET/18F
      • 5.2.1.1.2. ¬68Ga
      • 5.2.1.1.3. ¬68Cu
      • 5.2.1.1.4. ¬11Ga
      • 5.2.1.1.5. Others
      • 5.2.1.2. SPECT Radiopharmaceuticals
      • 5.2.1.2.1. Technetium-99m
      • 5.2.1.2.2. Iodine-123
      • 5.2.1.2.3. Xenon-133
      • 5.2.1.2.4. Thalium-201
      • 5.2.1.2.5. Others
    • 5.2.2. Therapeutic Nuclear Medicine
      • 5.2.2.1. Alpha Emitters
      • 5.2.2.2. Beta Emitters
      • 5.2.2.3. Brachytherapy Isotopes
    • 5.2.3. By Applications
      • 5.2.3.1. Neurology
      • 5.2.3.2. Cardiology
      • 5.2.3.3. Oncology
      • 5.2.3.4. Thyroid
      • 5.2.3.5. Bone Scans
      • 5.2.3.6. Others
    • 5.2.4. By End-users
      • 5.2.4.1. Hospitals
      • 5.2.4.2. Diagnostics Centers
      • 5.2.4.3. Others
    • 5.2.5. By Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia Pacific
      • 5.2.5.4. South America
      • 5.2.5.5. Middle East & Africa
  • 5.3. By Company Market Share (%), 2023
  • 5.4. North America*
    • 5.4.1. Market Size & Forecast
      • 5.4.1.1. By Value
      • 5.4.1.2. By Volume
    • 5.4.2. By Type
      • 5.4.2.1. Diagnostic Nuclear Medicine
      • 5.4.2.1.1. PET Radiopharmaceuticals
      • 5.4.2.1.1.1. FDG-PET/18F
      • 5.4.2.1.1.2. ¬68Ga
      • 5.4.2.1.1.3. ¬68Cu
      • 5.4.2.1.1.4. ¬11Ga
      • 5.4.2.1.1.5. Others
      • 5.4.2.1.2. SPECT Radiopharmaceuticals
      • 5.4.2.1.2.1. Technetium-99m
      • 5.4.2.1.2.2. Iodine-123
      • 5.4.2.1.2.3. Xenon-133
      • 5.4.2.1.2.4. Thalium-201
      • 5.4.2.1.2.5. Others
      • 5.4.2.2. Therapeutic Nuclear Medicine
      • 5.4.2.2.1. Alpha Emitters
      • 5.4.2.2.2. Beta Emitters
      • 5.4.2.2.3. Brachytherapy Isotopes
    • 5.4.3. By Applications
      • 5.4.3.1. Neurology
      • 5.4.3.2. Cardiology
      • 5.4.3.3. Oncology
      • 5.4.3.4. Thyroid
      • 5.4.3.5. Bone Scans
      • 5.4.3.6. Others
    • 5.4.4. By End-users
      • 5.4.4.1. Hospitals
      • 5.4.4.2. Diagnostics Centers
      • 5.4.4.3. Others
    • 5.4.5. United States*
      • 5.4.5.1. By Type
      • 5.4.5.1.1. Diagnostic Nuclear Medicine
      • 5.4.5.1.1.1. PET Radiopharmaceuticals
      • 5.4.5.1.1.1.1. FDG-PET/18F
      • 5.4.5.1.1.1.2. ¬68Ga
      • 5.4.5.1.1.1.3. ¬68Cu
      • 5.4.5.1.1.1.4. ¬11Ga
      • 5.4.5.1.1.1.5. Others
      • 5.4.5.1.1.2. SPECT Radiopharmaceuticals
      • 5.4.5.1.1.2.1. Technetium-99m
      • 5.4.5.1.1.2.2. Iodine-123
      • 5.4.5.1.1.2.3. Xenon-133
      • 5.4.5.1.1.2.4. Thalium-201
      • 5.4.5.1.1.2.5. Others
      • 5.4.5.1.2. Therapeutic Nuclear Medicine
      • 5.4.5.1.2.1. Alpha Emitters
      • 5.4.5.1.2.2. Beta Emitters
      • 5.4.5.1.2.3. Brachytherapy Isotopes
      • 5.4.5.2. By Applications
      • 5.4.5.2.1. Neurology
      • 5.4.5.2.2. Cardiology
      • 5.4.5.2.3. Oncology
      • 5.4.5.2.4. Thyroid
      • 5.4.5.2.5. Bone Scans
      • 5.4.5.2.6. Others
      • 5.4.5.3. By End-users
      • 5.4.5.3.1. Hospitals
      • 5.4.5.3.2. Diagnostics Centers
      • 5.4.5.3.3. Others
    • 5.4.6. Canada
    • 5.4.7. Mexico

All segments will be provided for all regions and countries covered:

  • 5.5. Europe
    • 5.5.1. Germany
    • 5.5.2. France
    • 5.5.3. Italy
    • 5.5.4. United Kingdom
    • 5.5.5. Russia
    • 5.5.6. Netherlands
    • 5.5.7. Spain
    • 5.5.8. Turkey
    • 5.5.9. Poland
  • 5.6. South America
    • 5.6.1. Brazil
    • 5.6.2. Argentina
  • 5.7. Asia-Pacific
    • 5.7.1. India
    • 5.7.2. China
    • 5.7.3. Japan
    • 5.7.4. Australia
    • 5.7.5. Vietnam
    • 5.7.6. South Korea
    • 5.7.7. Indonesia
    • 5.7.8. Philippines
  • 5.8. Middle East & Africa
    • 5.8.1. Saudi Arabia
    • 5.8.2. UAE
    • 5.8.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Type
  • 6.2. By Application
  • 6.3. By End-users
  • 6.4. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis - Volume and Value
  • 7.3. Supply/Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges, Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. GE Healthcare
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Cardinal Health
  • 13.3. Jubilant Life Sciences Ltd
  • 13.4. Curium Pharma
  • 13.5. Nordion Inc.
  • 13.6. Bracco Imaging S.P.A
  • 13.7. NTP Radioisotopes SOC Ltd.
  • 13.8. EczacIbasI-Monrol Nuclear Products
  • 13.9. Lantheus Medical Imaging Inc
  • 13.10. Eckert & Ziegler
  • 13.11. Mallinckrodt

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer